The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.

abstract：:Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

journal_title：International clinical psychopharmacology

authors： Varia I,Rauscher F

更新日期：2002-05-01 00:00:00

abstract：:Treatment of psychotic symptoms with traditional neuroleptics has been complicated by acute extrapyramidal syndromes (EPS) and late occurring tardive dyskinesia. These widely prevalent disorders have both motor and mental components which impose additional impairments on patients who are already substantially limited ...

journal_title：International clinical psychopharmacology

authors： Casey DE

更新日期：1997-02-01 00:00:00

abstract：:Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...

journal_title：International clinical psychopharmacology

authors： Linden M

更新日期：1999-06-01 00:00:00

abstract：:Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

journal_title：International clinical psychopharmacology

authors： Fineberg N

更新日期：1996-12-01 00:00:00

abstract：:The prevalence of tardive dyskinesia in a consecutive series of 69 patients with bipolar affective disorder admitted to a catchment area service was found to be 19%. Prevalence increased with age and was related to the age of onset of bipolar disorder and number of previous episodes. Patients with tardive dyskinesia w...

journal_title：International clinical psychopharmacology

authors： Hunt N,Silverstone T

更新日期：1991-04-01 00:00:00

abstract：:The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

journal_title：International clinical psychopharmacology

authors： Ashford JJ

更新日期：1995-01-01 00:00:00

abstract：:Studies on humans show that depressive disorder is associated with an increased risk of developing cognitive dysfunction, and animal studies suggest that antidepressants may have neuroprotective abilities. On the basis of these observations, it was hypothesized that treatment with antidepressants may decrease the risk...

journal_title：International clinical psychopharmacology

authors： Kessing LV,Forman JL,Andersen PK

更新日期：2011-11-01 00:00:00

abstract：:Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

journal_title：International clinical psychopharmacology

authors： Eriksson E

更新日期：1999-05-01 00:00:00

abstract：:The treatment of depressed patients with a fixed dose of amitriptyline is compared to treatment with an individualized dose calculated by means of a simple pharmacokinetic test. Clinical response and the development of side-effects are compared between the two groups of patients. Although the numbers in the groups wer...

journal_title：International clinical psychopharmacology

authors： Roy D,Dawling S

更新日期：1987-10-01 00:00:00

abstract：:While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patient...

journal_title：International clinical psychopharmacology

authors： Papakostas GI,Petersen T,Worthington JJ,Roffi PA,Alpert JE,Fava M,Nierenberg AA

更新日期：2003-09-01 00:00:00

abstract：:Fluoxetine, a selective inhibitor of serotonin (5-HT) uptake, was compared with placebo in a randomized double-blind longitudinal trial in 12 healthy volunteers. Sleep polygraphic recordings were performed at home twice before and once after 6 days of medication. After 6 days fluoxetine significantly decreased the amo...

journal_title：International clinical psychopharmacology

authors： Vasar V,Appelberg B,Rimón R,Selvaratnam J

更新日期：1994-09-01 00:00:00

abstract：:One hundred and sixty patients with a primary diagnosis of obsessive-compulsive disorder were enrolled in a multicentre, randomized, double-blind, placebo-controlled study of fluvoxamine. After a placebo washout phase, patients were randomized to treatment with placebo or fluvoxamine (100-300 mg/day) for 10 weeks. Sev...

journal_title：International clinical psychopharmacology

authors： Goodman WK,Kozak MJ,Liebowitz M,White KL

更新日期：1996-03-01 00:00:00

abstract：:This double-blind study was performed on 10 aged insomniac patients who received, during 15 days, either triazolam (0.25 mg) or zopiclone (7.5 mg) at bed time. This in-patient period was bounded by two ambulatory periods of 5 days each, and two in-patient periods of 3 days each, during which the patients received a pl...

journal_title：International clinical psychopharmacology

authors： Mouret J,Ruel D,Maillard F,Bianchi M

更新日期：1990-04-01 00:00:00

abstract：:Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...

journal_title：International clinical psychopharmacology

authors： Lucey JV,O'Keane V,O'Flynn K,Clare AW,Dinan TG

更新日期：1991-07-01 00:00:00

abstract：:Most antidepressants in clinical use are believed to function by enhancing neurotransmission of serotonin [5-hydroxytryptamine (5-HT)] and/or norepinephrine (NE) via inhibition of neurotransmitter reuptake. Agents that affect reuptake of both 5-HT and NE (serotonin-norepinephrine reuptake inhibitors) have been postula...

journal_title：International clinical psychopharmacology

authors： Trivedi MH,Desaiah D,Ossanna MJ,Pritchett YL,Brannan SK,Detke MJ

更新日期：2008-05-01 00:00:00

abstract：:The use of certain atypical antipsychotics has been associated with metabolic disturbances. We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine. Three hundred and seventy-seven adult patients with schizophrenia were randomized to eithe...

journal_title：International clinical psychopharmacology

authors： Peuskens J,De Hert M,Mortimer A,SOLIANOL Study Group.

更新日期：2007-05-01 00:00:00

abstract：:C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

journal_title：International clinical psychopharmacology

authors： Kim SH,Reaven G,Lindley S

更新日期：2011-01-01 00:00:00

abstract：:In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

journal_title：International clinical psychopharmacology

authors： Brown D,Silverstone T,Cookson J

更新日期：1989-07-01 00:00:00

abstract：:Characteristic response patterns are described for two antidepressant drugs and placebo in post-traumatic stress disorder. Early onset and steady improvement occurred on a global rating scale for both drugs and placebo in those who ultimately met responder criteria at the end of treatment. In certain cases, the magnit...

journal_title：International clinical psychopharmacology

authors： Davidson JR,Malik ML,Sutherland SN

更新日期：1997-11-01 00:00:00

abstract：:In a double-blind multi-centre study of general practice patients with DSM-III-R major depressive disorder, sertraline (50 or 100 mg/day) was compared with dothiepin (75 or 150 mg/day) and with placebo. There were 83, 96 and 90 patients evaluated in the respective treatment groups; treatment lasted 6 weeks. Patients w...

journal_title：International clinical psychopharmacology

authors： Doogan DP,Langdon CJ

更新日期：1994-07-01 00:00:00

abstract：:Clozapine therapy does not produce the rapid response that may be required in severely disturbed patients. The latter, not uncommonly, obstruct treatment by refusing to give blood for haematological monitoring or refusing to swallow tablets. Whereas electroconvulsive therapy (ECT) may be used for rapid behavioural con...

journal_title：International clinical psychopharmacology

authors： James DV,Gray NS

更新日期：1999-03-01 00:00:00

abstract：:The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosi...

journal_title：International clinical psychopharmacology

authors： Peuskens J,Van Baelen B,De Smedt C,Lemmens P

更新日期：2000-11-01 00:00:00

abstract：:Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine...

journal_title：International clinical psychopharmacology

authors： Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

更新日期：2008-11-01 00:00:00

abstract：:Benzodiazepines are commonly used for behavioral and psychiatric symptoms of dementia, despite their numerous adverse effects and the lack of evidence regarding their efficacy in this context. We studied longitudinal benzodiazepines exposure in incident cases of Alzheimer's disease and related syndromes (ADRS) in Fran...

journal_title：International clinical psychopharmacology

authors： Poncet M,Gardette V,Couret A,Renoux A,Lapeyre-Mestre M,Gallini A

更新日期：2020-09-01 00:00:00

abstract：:The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode s...

journal_title：International clinical psychopharmacology

authors： Malla A,Ota A,Nagamizu K,Perry P,Weiller E,Baker RA

更新日期：2016-11-01 00:00:00

abstract：:Forty-one delirious patients who received risperidone treatment and 36 who received haloperidol treatment were retrospectively analysed. Ten-point visual analog scales (scored 0 for none to 10 for extremely severe) for hyperactive and hypoactive syndromes of delirium were used for efficacy evaluation. Psychiatrists sc...

journal_title：International clinical psychopharmacology

authors： Liu CY,Juang YY,Liang HY,Lin NC,Yeh EK

更新日期：2004-05-01 00:00:00

abstract：:Treatment-resistant depression is an important clinical problem presenting a major challenge to clinical psychiatry. While several strategies have been attempted, including medication switch, antidepressant polypharmacy and various augmentative regimens, success remains limited. Amantadine (AMN), an agent traditionall...

journal_title：International clinical psychopharmacology

authors： Stryjer R,Strous RD,Shaked G,Bar F,Feldman B,Kotler M,Polak L,Rosenzcwaig S,Weizman A

更新日期：2003-03-01 00:00:00

abstract：:Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

journal_title：International clinical psychopharmacology

authors： Dahl AA

更新日期：1996-06-01 00:00:00

abstract：:The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

journal_title：International clinical psychopharmacology

authors： Whitworth AB,Fleischhacker WW

更新日期：1995-01-01 00:00:00

abstract：:In a randomized prospective clinical trial with an observation period of 2.5 years, a subgroup analysis was carried out for the 114 patients with bipolar I disorder (DSM-IV) regarding the prophylactic efficacy of lithium and carbamazepine. Treatment outcome was evaluated taking rehospitalization, recurrence, subclinic...

journal_title：International clinical psychopharmacology

authors： Greil W,Kleindienst N

更新日期：1999-09-01 00:00:00